Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen
Interim phase II data suggest the antitumor activity of panitumumab in metastatic colorectal cancer
July 4th, 2006
Amgen (AMGN) announced interim results from two phase II studies of panitumumab, an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr). Results from both studies suggest that antitumor activity of panitumumab was independent of tumor EGFr expression levels in patients with metastatic colorectal cancer (mCRC) who have failed standard chemotherapy. These data were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology. "EGFr staining is an immunohistochemical test to determine the amount of that protein on the surface of cancer cells and has been used to try to figure out...
Source: Pharma Law Weekly (2006-07-04)
|
